Shuwen Liu Selected Research

Therapeutics

4/2024	Itaconate alleviates diet-induced obesity via activation of brown adipocyte thermogenesis.
3/2024	Dual-directional regulation of spinal cord injury and the gut microbiota.
9/2023	Discovery of novel aporphine alkaloid derivative as potent TLR2 antagonist reversing macrophage polarization and neutrophil infiltration against acute inflammation.
3/2023	Pterostilbene effectively inhibits influenza A virus infection by promoting the type I interferon production.
1/2023	Glycosylated, Lipid-Binding, CDR-Like Domains of SARS-CoV-2 ORF8 Indicate Unique Sites of Immune Regulation.
12/2022	Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.
12/2022	Emerging antiviral therapies and drugs for the treatment of influenza.
9/2022	Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy.
1/2022	Discovery and optimization of new 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinoline derivatives as potent influenza virus PAN inhibitors.
1/2022	PARP1 Might Substitute HSF1 to Reactivate Latent HIV-1 by Binding to Heat Shock Element.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuwen Liu Research Topics

Disease

81	Infections 04/2024 - 01/2004
32	Neoplasms (Cancer) 01/2023 - 02/2013
28	Human Influenza (Influenza) 01/2024 - 04/2010
27	Virus Diseases (Viral Diseases) 03/2024 - 03/2005
16	Inflammation (Inflammations) 12/2023 - 11/2012
10	COVID-19 01/2023 - 01/2020
8	HIV Infections (HIV Infection) 01/2022 - 08/2002
8	Acquired Immunodeficiency Syndrome (AIDS) 10/2021 - 08/2002
5	Shock 12/2023 - 02/2021
5	Esophageal Neoplasms (Esophageal Cancer) 03/2016 - 03/2011
4	Obesity 04/2024 - 07/2020
4	Breast Neoplasms (Breast Cancer) 01/2023 - 10/2019
4	Neoplasm Metastasis (Metastasis) 01/2021 - 10/2019
4	Proteinuria 01/2018 - 06/2002
4	Severe Acute Respiratory Syndrome 07/2005 - 11/2004
3	Lupus Nephritis 03/2024 - 12/2022
3	Fibrosis (Cirrhosis) 03/2024 - 04/2005
3	Communicable Diseases (Infectious Diseases) 12/2023 - 03/2018
3	Autoimmune Diseases (Autoimmune Disease) 09/2023 - 05/2012
3	Edema (Dropsy) 09/2023 - 10/2013
3	Dengue (Dengue Fever) 01/2023 - 02/2018
3	Pneumonia (Pneumonitis) 01/2022 - 01/2021
3	Hypoxia (Hypoxemia) 12/2020 - 06/2015
3	IGA Glomerulonephritis (IGA Nephropathy) 04/2004 - 06/2002
2	Hyperlipidemias (Hyperlipidemia) 04/2024 - 07/2020
2	Herpes Simplex 03/2024 - 01/2023
2	Dysbiosis 03/2024 - 11/2021
2	Stomach Neoplasms (Stomach Cancer) 01/2023 - 02/2013
2	Zika Virus Infection 01/2023 - 01/2020
2	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 01/2022
2	Atherosclerosis 09/2022 - 07/2020
2	Cardiovascular Diseases (Cardiovascular Disease) 08/2022 - 01/2014

Drug/Important Bio-Agent (IBA)

33	Antiviral Agents (Antivirals)IBA 12/2023 - 03/2004
30	Proteins (Proteins, Gene)FDA Link 03/2024 - 06/2002
19	Peptides (Polypeptides)IBA 03/2024 - 01/2004
14	Amyloid (Amyloid Fibrils)IBA 03/2024 - 11/2012
13	VaccinesIBA 01/2023 - 03/2005
10	CytokinesIBA 03/2024 - 12/2017
9	Hemagglutinins (Hemagglutinin)IBA 12/2023 - 01/2012
8	Glycoproteins (Glycoprotein)IBA 11/2021 - 11/2004
8	Anti-Infective Agents (Microbicides)IBA 09/2021 - 05/2005
7	Therapeutic UsesIBA 06/2023 - 06/2002
7	Messenger RNA (mRNA)IBA 12/2022 - 01/2017
6	LipopolysaccharidesIBA 12/2023 - 10/2013
6	LipidsIBA 01/2023 - 06/2002
5	InterferonsIBA 03/2023 - 06/2012
5	OvalbuminIBA 01/2021 - 04/2011
5	Cisplatin (Platino)FDA LinkGeneric 03/2016 - 03/2011
4	Interferon Type IIBA 04/2024 - 01/2018
4	LigandsIBA 03/2024 - 12/2013
4	EndonucleasesIBA 01/2024 - 03/2020
4	RNA (Ribonucleic Acid)IBA 01/2023 - 05/2013
4	obatoclaxIBA 04/2019 - 12/2013
4	CreatinineIBA 03/2014 - 06/2002
3	EnzymesIBA 03/2024 - 01/2021
3	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2024 - 01/2018
3	InflammasomesIBA 12/2023 - 01/2021
3	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2023 - 01/2019
3	Polysaccharides (Glycans)IBA 02/2023 - 06/2005
3	SaponinsIBA 01/2023 - 01/2019
3	Liver X ReceptorsIBA 01/2023 - 01/2021
3	Neuraminidase (Sialidase)IBA 01/2023 - 08/2013
3	gadolinium oxide (gadolinia)IBA 07/2022 - 01/2020
3	NucleosidesIBA 11/2021 - 09/2012
3	AntigensIBA 06/2021 - 05/2013
3	CarrageenanIBA 03/2020 - 10/2013
3	3-hydroxyphthalic anhydrideIBA 01/2020 - 04/2011
3	ADS J1IBA 01/2019 - 05/2014
3	3- fluoro- N- (2- (1- piperidinyl)ethyl)- 5- (trifluoromethyl)benzamideIBA 12/2017 - 06/2011
3	Celecoxib (Celebrex)FDA Link 01/2016 - 03/2011
3	AntibodiesIBA 05/2013 - 11/2004
2	RibonucleoproteinsIBA 03/2024 - 01/2019
2	EpitopesIBA 12/2023 - 03/2005
2	SolutionsIBA 12/2023 - 01/2020
2	Sirtuin 3IBA 10/2023 - 10/2020
2	Toll-Like Receptor 2IBA 09/2023 - 05/2019
2	AntioxidantsIBA 01/2023 - 12/2017
2	GlucansIBA 01/2023 - 12/2020
2	Viral ProteinsIBA 01/2023 - 09/2021
2	MicroRNAs (MicroRNA)IBA 12/2022 - 01/2022
2	AcidsIBA 07/2022 - 01/2020
2	carbopol 940 (sodium polyacrylate)IBA 02/2022 - 01/2020
2	Contrast MediaIBA 02/2022 - 11/2021
2	ResveratrolIBA 01/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2021
2	SMU-Z1IBA 10/2021 - 05/2019
2	Sirtuin 1IBA 09/2021 - 06/2015
2	HydrogelsIBA 06/2021 - 09/2020
2	GoldIBA 06/2021 - 03/2019
2	myricetinIBA 05/2021 - 01/2018
2	SARS-CoV-2 spike proteinIBA 05/2021 - 04/2020
2	TriterpenesIBA 04/2021 - 01/2019
2	AmidesIBA 04/2021 - 01/2019
2	Membrane Proteins (Integral Membrane Proteins)IBA 04/2021 - 12/2013

Therapy/Procedure

39	Therapeutics 04/2024 - 06/2002
7	Drug Therapy (Chemotherapy) 12/2024 - 01/2004
6	Immunotherapy 01/2023 - 06/2021
3	Aftercare (After-Treatment) 01/2023 - 06/2002
3	Highly Active Antiretroviral Therapy (HAART) 01/2019 - 05/2011
2	Injections 06/2021 - 01/2019